NeuroProtect – A novel therapy to prevent Chemotherapy-Induced Peripheral Neuropathy

The NeuroProtect project aims to prevent chemotherapy-induced peripheral neuropathy by using Localised Microvascular Compression Therapy to reduce drug delivery to peripheral nerves during treatment.

Subsidie
€ 150.000
2023

Projectdetails

Introduction

Chemotherapy induced peripheral neuropathy (CIPN) is a debilitating neural condition that affects millions of European cancer patients every year. It is considered by patients and oncologists to be the most significant long-term impact of cancer treatment and often results in devastating consequences for patients, including an inability to work or perform the basic tasks of daily living.

Urgent Need

With chemotherapy usage set to increase by 53% by 2040, CIPN remains a clear and urgent unmet patient need. CIPN is the loss of sensation and movement in the hands and feet induced by chemotherapy treatment and is often associated with chronic neuropathic pain.

Mechanism of CIPN

Chemotherapy drugs enter the bloodstream and target all fast-growing, rapidly multiplying cells – a known characteristic of cancerous cells. However, many cells of this nature occur naturally in the body, including peripheral nerve cells. Thus, a well-known side effect of chemotherapy is the demyelination of these peripheral nerves (i.e., the destruction of the protective coating of nerve cells).

Localised Microvascular Compression Therapy (LMCT)

Localised Microvascular Compression Therapy (LMCT) is a concept developed by the PI focused on temporarily reducing blood flow and unwanted chemotherapy drug delivery at the peripheral nerve fibres during chemotherapy treatment.

Mechanism of Action

By applying a consistent low-level pressure (between 40 and 60 mmHg) across the skin surface of the hands and feet, the local micro-blood vessels (which deliver chemotherapy drugs to the nerve fibres) are temporarily occluded. This causes local chemotherapy delivery to be drastically reduced, thus preventing destruction of long-chain myelin and maintaining neural function.

Note: Short-term and controlled blood flow reductions have been shown to cause no tissue damage.

Conclusion

In this way, the NeuroProtect project will deliver a safe and pain-free solution to prevent CIPN during chemotherapy treatment.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-11-2023
Einddatum30-4-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITY OF GALWAYpenvoerder

Land(en)

Ireland

Vergelijkbare projecten binnen European Research Council

ERC Advanced...

Overcoming Mechanically-Induced Resistance to Chemo-Immunotherapy in Pancreatic Cancer

This project aims to identify and overcome mechanoresistance in pancreatic cancer using bioengineering methods to enhance chemotherapy efficacy and improve patient-specific treatment strategies.

€ 2.500.000
ERC Proof of...

Live biotherapeutics to potentiate cancer immunotherapy

The project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models.

€ 150.000
ERC Starting...

Decrypting neuro-cancer crosstalk in pediatric cancers of the peripheral nervous system

This project aims to explore the interactions between neurobiology and neuroblastoma to identify therapeutic targets and define subtypes benefiting from neuro-related treatments.

€ 1.836.141
ERC Proof of...

Targeted nanohorns for lithium neutron capture therapy

TARLIT aims to enhance neutron capture therapy for cancer by using nanoparticles to deliver enriched lithium compounds, improving treatment precision and efficacy against tumors.

€ 150.000
ERC Starting...

Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapy

This project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling.

€ 1.500.000

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss

LILY is a portable device that prevents chemotherapy-induced hair loss by using localized microvasculature compression therapy to inhibit drug delivery to hair follicles.

€ 2.499.999
Mkb-innovati...

Behandeling diabetische neuropathie m.b.v. EVNS

Neurecon onderzoekt technische en financiële risico's van een veelbelovende behandeling voor diabetische neuropathie.

€ 20.000
EIC Accelerator

Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1

The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments.

€ 2.500.000
EIC Transition

Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples

The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.

€ 2.499.999
EIC Pathfinder

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

€ 5.972.875